Merck’s 4Q17 Estimates: Vaccines


Feb. 1 2018, Updated 7:33 a.m. ET

Merck’s vaccines

Merck & Co.’s (MRK) vaccines business is part of its Pharmaceutical segment and includes Gardasil, ProQuad/Varivax, RotaTeq, Pneumovax 23, and Zostavax. Total revenues from the vaccines portfolio are expected to decrease in 4Q17 due to lower sales of Gardasil. However, the decrease in revenues could be substantially offset by an increase in sales of Zostavax, Pneumovax 23, RotaTeq, and ProQuad/Varivax.

The above chart compares revenues for Gardasil since 4Q15.

Article continues below advertisement


The Gardasil franchise includes vaccines for the prevention of certain strains of sexually transmitted HPV (human papillomavirus) infections, which include various forms of cancer, including cervical cancer, anal cancer, penile cancer, vaginal cancer, genital warts, and vulvar cancer, induced by HPV. Gardasil revenues are expected to report marginal growth in 4Q17.

Other vaccines

Merck’s human vaccines portfolio also includes ProQuad/Varivax, RotaTeq, Pneumovax 23, and Zostavax. Zostavax is used for the prevention of herpes zoster infection in adults aged 50 years and older. Zostavax revenues are expected to increase in 4Q17 due to a strong demand for the vaccine.

Pneumovax 23, a pneumococcal vaccine, is expected to report growth in revenues in 4Q17 due to strong demand.

The VanEck Vectors Morningstar Wide Moat ETF (MOAT) holds 26.1% of its total investments in healthcare companies. It holds 2.3% in Merck & Co. (MRK), 2.3% in Eli Lilly (LLY), 2.3% in Bristol-Myers Squibb (BMY), and 2.4% in Pfizer (PFE).


More From Market Realist